R&D News | pharmaphorum

News

Coronavirus won't be circulating in UK by August, says outgo...

Coronavirus won’t be circulating in the UK by August, according to the outgoing chief of the country’s vaccine rollout scheme, Dr Clive Dix.

News

CRISPR Therapeutics begins natural killer cell cancer tie-up...

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer.

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Small Pharma stock market launch funds DMT-based depression ...

UK-based Small Pharma has launched on the Toronto's TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-Dimethyltryptamine (DMT) to tre

News

Sanofi begins three-year immunology R&D tie-up with Stanford

Sanofi has begun a three-year research collaboration with Stanford University School of Medicine, working on better understanding of immunology and inflammation through open scientific exch

News

Ex-Merck R&D chief Perlmutter takes reins at drug discovery ...

A new drug discovery firm, Eikon Therapeutics, has launched with former Merck & Co research chief Roger Perlmutter at the helm.

News

Nebuliser being filled. Copyright Vectura (002)

New UK biotech Inspira uncloaks with deal to develop inhaled...

UK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled therapy for COVID-19 that could be ready for human testing within 12 months.&

Coronavirus won't be circulating in UK by August, says outgo...

CRISPR Therapeutics begins natural killer cell cancer tie-up...

Small Pharma stock market launch funds DMT-based depression ...

Sanofi begins three-year immunology R&D tie-up with Stanford

Ex-Merck R&D chief Perlmutter takes reins at drug discovery ...

New UK biotech Inspira uncloaks with deal to develop inhaled...

UCB buys cell therapy biotech Candid for $2bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks